Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Provided By GlobeNewswire
Last update: Jan 16, 2025
Company on track to report topline data in first half of 2025
Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108
Read more at globenewswire.com0.7901
-0.09 (-10.05%)
Find more stocks in the Stock Screener
PALI Latest News and Analysis
